Sanofi India reported strong financial results for the quarter ended June 30, 2026, with profits before tax increasing by 19% year-on-year. The company highlighted robust growth in its diabetes portfolio, particularly with its insulin products, contributing to a healthy profit momentum. The Board also approved the re-constitution of key committees effective October 1, 2026.
Sanofi India Reports Strong Q2 2026 Performance
Sanofi India Limited announced its financial results for the quarter and half year ended June 30, 2026, showcasing a significant improvement in profitability and sustained growth in its key business segments. The Board of Directors, at its meeting held on August 4, 2026, considered and approved the unaudited financial results, which reflect the company’s strong performance.
Financial Highlights
For the quarter ended June 30, 2026, Sanofi India reported domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. Profits before tax and exceptional items saw a substantial increase of 19%, rising to INR 112 crores from INR 94 crores in the corresponding quarter of the previous year. The profit before tax as a percentage of net sales improved to 27% in Q2 2026, up from 24% in Q2 2025. This improvement is attributed to a favorable product mix and disciplined cost management, with operating expenses declining by 5%.
Diabetes Portfolio Drives Growth
The company’s insulin portfolio continued its strong trajectory, delivering double-digit growth of 14% for the second consecutive quarter. This performance reinforces Sanofi’s leadership in the basal analog market, holding a 58% value market share and 61% volume market share. Growth was propelled by key products such as Lantus®, Toujeo®, and Apidra®, alongside the successful performance of Soliqua®.
Furthermore, the public sector business experienced significant acceleration with growth of 70%, driven by new account acquisitions for Toujeo® and Soliqua® under the CARE Accounts initiative. Strategic partnerships in cardiovascular, oral anti-diabetes, and central nervous system segments have also established a strong foundation, with partnership revenues growing by 2%.
Committee Re-Constitution
In line with regulatory requirements, the Board of Directors approved the re-constitution of the following committees with effect from October 1, 2026:
Stakeholders Relationship Committee
- Mr. Siraj Chaudhry: Chairman
- Mr. Deepak Arora: Member
- Ms. Sudipta Chakraborty: Member
Risk Management Committee
- Ms. Rajani Kesari: Chairperson
- Mr. Siraj Chaudhry: Member
- Mr. Deepak Arora: Member
- Mr. Mahadev Gawade: Member
Additionally, pursuant to Regulation 30(5) of the Listing Regulations, the name of Mr. Rachid Ayari will be deleted from the list of Key Managerial Personnels authorized to determine materiality of an event or information upon his stepping down as Whole Time Director and Chief Financial Officer on September 30, 2026.
The Board meeting commenced at 4:00 p.m. and concluded at 6:58 p.m. on August 4, 2026.
Source: BSE
